Article
A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C in liver transplant recipients at two university centers in Northeastern Brazil.
Revista do Instituto de Medicina Tropical de Sao Paulo - 1 Jan 2021
Silva Isabella Patrícia Lima, Batista Andrea Dória, Lopes Edmundo Pessoa, Filgueira Norma Arteiro, Carvalho Bernardo Times de, Santos Joelma Carvalho, Medeiros Tibério Batista de, Melo Clarissa Ramos Lacerda de, Lima Martha Sá de, Lima Kledoaldo, Lacerda Claudio, Lacerda Heloisa Ramos
Abstract excerpt
The efficacy of direct-acting antivirals (DAAs) in the treatment of chronic hepatitis C (CHC) in liver transplant recipients is poorly understood, and several factors, including immunosuppression, drug interactions, elevated viraemia, and intolerance to ribavirin (RBV), can reduce cure rates. We conducted a real-life study on liver transplant recipients with CHC treated with a combination of sofosbuvir (SOF) and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
